{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:38:25Z","timestamp":1671266305610},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1097\/md.0000000000008762","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T19:13:26Z","timestamp":1511378006000},"page":"e8762","source":"Crossref","is-referenced-by-count":1,"title":["Stroke risks and patterns of warfarin therapy among atrial fibrillation patients post radiofrequency ablation"],"prefix":"10.1097","volume":"96","author":[{"given":"Juan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiandong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-65-20210309","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-65-20210309","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCOUTCOMES.110.937680","article-title":"Warfarin discontinuation after starting warfarin for atrial fibrillation","volume":"3","author":"Fang","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R3-65-20210309","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11239-015-1244-0","article-title":"The changing characteristics of atrial fibrillation patients treated with warfarin","volume":"40","author":"Putnam","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"R4-65-20210309","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/00325481.2015.1029863","article-title":"Implications for your practice: Important changes in the 2014 guideline for the management of patients with atrial fibrillation","volume":"127","author":"Littrell","year":"2015","journal-title":"Postgrad Med"},{"key":"R5-65-20210309","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/eurheartj\/ehu139","article-title":"Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study","volume":"36","author":"Friberg","year":"2015","journal-title":"Eur Heart J"},{"key":"R6-65-20210309","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0140-6736(11)61514-6","article-title":"Atrial fibrillation","volume":"379","author":"Lip","year":"2012","journal-title":"Lancet"},{"key":"R7-65-20210309","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"R8-65-20210309","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jacc.2008.05.042","article-title":"Epidemiology, risk factors for stroke, and management of atrial fibrillation in China","volume":"52","author":"Hu","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R9-65-20210309","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1747-4949.2011.00716.x","article-title":"Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the ChinaQUEST (Quality evaluation of stroke care and treatment) registry study","volume":"8","author":"Gao","year":"2013","journal-title":"Int J Stroke"},{"key":"R10-65-20210309","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.10.006","article-title":"Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry","volume":"23","author":"Wang","year":"2014","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R11-65-20210309","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.04.030","article-title":"Suboptimal anticoagulant management in Japanese patients with nonvalvular atrial fibrillation receiving warfarin for stroke prevention","volume":"26","author":"Hirano","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R12-65-20210309","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1093\/eurheartj\/ehl015","article-title":"Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation","volume":"27","author":"Nieuwlaat","year":"2006","journal-title":"Eur Heart J"},{"key":"R13-65-20210309","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2006.11.045","article-title":"Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database","volume":"49","author":"Rowan","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R14-65-20210309","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"R15-65-20210309","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/europace\/eun086","article-title":"Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world","volume":"10","author":"Meiltz","year":"2008","journal-title":"Europace"},{"key":"R16-65-20210309","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5603\/CJ.a2014.0034","article-title":"Roles of the CHADS2 and CHA2DS2-VASc scores in post-myocardial infarction patients: risk of new occurrence of atrial fibrillation and ischemic stroke","volume":"21","author":"Lau","year":"2014","journal-title":"Cardiol J"},{"key":"R17-65-20210309","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.thromres.2014.01.007","article-title":"CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"133","author":"Puurunen","year":"2014","journal-title":"Thromb Res"},{"key":"R18-65-20210309","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjmed.2016.02.029","article-title":"Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study","volume":"129","author":"Saliba","year":"2016","journal-title":"Am J Med"},{"key":"R19-65-20210309","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"R20-65-20210309","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.amjmed.2014.05.003","article-title":"Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey","volume":"127","author":"Marcucci","year":"2014","journal-title":"Am J Med"},{"key":"R21-65-20210309","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCEP.113.001182","article-title":"Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry","volume":"7","author":"Kornej","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R22-65-20210309","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/heartjnl-2013-305303","article-title":"Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores","volume":"100","author":"Mitchell","year":"2014","journal-title":"Heart"},{"key":"R23-65-20210309","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-03-0175","article-title":"The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study","volume":"107","author":"Olesen","year":"2012","journal-title":"Thromb Haemost"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:42:55Z","timestamp":1620960175000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201711270-00065"}},"subtitle":["A real-world experience"],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":23,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008762","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}